BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19118226)

  • 1. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
    Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
    Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
    Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
    Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.
    Ahn CH; Lowell JR; Ahn SS; Ahn SI; Hurst GA
    Am Rev Respir Dis; 1983 Dec; 128(6):1048-50. PubMed ID: 6650978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study.
    Griffith DE; Brown-Elliott BA; Wallace RJ
    Clin Infect Dis; 2003 Nov; 37(9):1178-82. PubMed ID: 14557961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
    Snider DE; Zierski M; Graczyk J; Bek E; Farer LS
    Eur J Respir Dis; 1986 Jan; 68(1):12-8. PubMed ID: 3512281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London.
    Davies BS; Roberts CH; Kaul S; Klein JL; Milburn HJ
    Scand J Infect Dis; 2012 Nov; 44(11):815-9. PubMed ID: 23078529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampin-resistant Mycobacterium kansasii.
    Wallace RJ; Dunbar D; Brown BA; Onyi G; Dunlap R; Ahn CH; Murphy DT
    Clin Infect Dis; 1994 May; 18(5):736-43. PubMed ID: 8075262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fever and thin-walled cavitary lung lesions].
    Ramos A; Daza R; Alvarez-Espejo T; Guzmán MF
    Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):363-4. PubMed ID: 19419797
    [No Abstract]   [Full Text] [Related]  

  • 10. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
    Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii.
    Ahn CH; Wallace RJ; Steele LC; Murphy DT
    Am Rev Respir Dis; 1987 Jan; 135(1):10-6. PubMed ID: 3800137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
    Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
    Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.
    Sauret J; Hernández-Flix S; Castro E; Hernández L; Ausina V; Coll P
    Tuber Lung Dis; 1995 Apr; 76(2):104-8. PubMed ID: 7780090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient.
    Cosson MA; Bertrand JB; Martin C; Veziris N; Picard C; Goulvestre C; Coignard S; Benoit JP; Silvera S; Moro MR; Poyart C; Morand PC
    J Med Microbiol; 2012 Nov; 61(Pt 11):1617-1620. PubMed ID: 22859583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of the schedules of short and long term treatment for tuberculous meningoencephalitis at two hospitals of Lima--Peru.
    Morales S; Ramos W; Vílchez R; Pérez J; Alvarado M
    Neurologia; 2011 May; 26(4):220-6. PubMed ID: 21163196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment.
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):628-34. PubMed ID: 12102303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
    Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A study on short-course chemotherapy for pulmonary tuberculosis. Initial intensive regimens containing streptomycin].
    Suzuyama Y; Shigeno Y; Shigeno H; Nakazato H; Nagasawa M; Koga H; Tomita H; Tomonaga A; Yamaguchi K; Izumikawa K
    Kekkaku; 1984 Apr; 59(4):277-87. PubMed ID: 6748457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.